PFF Clinical Trial Innovation (CTI) Webinar Series February 2026 | Virtual
Please join the Pulmonary Fibrosis Foundation (PFF) and industry representatives for the PFF Clinical Trial Innovation (CTI) Webinar Series on Wednesday, February 11, 2026. You will learn about the development of innovative therapies and advancements in pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. The webinar will feature the following clinical trials:
FOCUSIPF: A Phase 2a Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
- Trial Sponsor: AbbVie
- Presenter: Flavia Soares, MD, PhD
- Medical Director, AbbVie
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis (AURORA)
- Trial Sponsor: Calluna Pharma
- Presenter: Mark Hamblin, MD, FCCP
- Associate Professor, University of Kansas
- Director of KU ILD and Rare Lung Disease Program, University of Kansas
ASPIRE-IPF
- Trial Sponsor: Vicore Pharma
- Presenter: Joshua Solomon, MD
- Professor of Medicine, University of Colorado
- Director of Interstitial Lung Disease Program, National Jewish Health
DISCLAIMER: Participation in the CTI Webinar Series and references to specific commercial entities (companies) or products do not reflect endorsement by the PFF. The PFF does not endorse or promote any products or services participants discuss in the CTI Webinar Series, and participants cannot suggest otherwise. Please note that any information contained in this presentation is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice. Always consult your personal physician or health care provider to determine if a clinical trial is right for you.